Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.48
- Piotroski Score 3.00
- Grade Buy
- Symbol (CYTK)
- Company Cytokinetics, Incorporated
- Price $48.75
- Changes Percentage (2.27%)
- Change $1.08
- Day Low $47.41
- Day High $48.78
- Year High $110.25
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $85.00
- High Stock Price Target $120.00
- Low Stock Price Target $45.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.40
- Trailing P/E Ratio -9.78
- Forward P/E Ratio -9.78
- P/E Growth -9.78
- Net Income $-526,244,000
Income Statement
Quarterly
Annual
Latest News of CYTK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History
Bayer has acquired rights to Cytokinetics' heart drug in Japan through a collaboration deal. The agreement includes an upfront payment of 50 million euros with potential additional payments based on d...
By Yahoo! Finance | 3 days ago -
Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
A recent article highlights Cytokinetics Inc. as a promising small-cap stock for investment. It discusses the impact of interest rate cuts on small and mid-cap stocks and provides insights from expert...
By Yahoo! Finance | 1 month ago -
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo Finance
Cytokinetics, Inc. shared positive results from the Phase 1 study of CK-4021586 at a medical conference. The study successfully evaluated safety, tolerability, and pharmacokinetics of CK-586, a drug b...
By Yahoo! Finance | 2 months ago